Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,864
  • Shares Outstanding, K 70,704
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -102 M
  • EBITDA $ -100 M
  • 60-Month Beta -0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.95

Options Overview Details

View History
  • Implied Volatility 287.51% ( +96.99%)
  • Historical Volatility 139.89%
  • IV Percentile 94%
  • IV Rank 30.83%
  • IV High 747.02% on 04/14/25
  • IV Low 82.66% on 03/25/25
  • Put/Call Vol Ratio 0.01
  • Today's Volume 559
  • Volume Avg (30-Day) 789
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 59,967
  • Open Int (30-Day) 58,201

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.27
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +67.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +9.02%
on 11/05/25
1.7143 -22.42%
on 10/13/25
-0.3500 (-20.83%)
since 10/10/25
3-Month
1.2200 +9.02%
on 11/05/25
2.9900 -55.52%
on 10/06/25
-0.2000 (-13.07%)
since 08/11/25
52-Week
1.2200 +9.02%
on 11/05/25
8.1800 -83.74%
on 11/12/24
-6.7000 (-83.44%)
since 11/11/24

Most Recent Stories

More News
Biomea Fusion to Participate at Jefferies London Healthcare Conference

SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3300 (-2.92%)
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys...

BMEA : 1.3300 (-2.92%)
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”)...

BMEA : 1.3300 (-2.92%)
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present...

BMEA : 1.3300 (-2.92%)
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company,...

BMEA : 1.3300 (-2.92%)
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s...

BMEA : 1.3300 (-2.92%)
Biomea Fusion Enters Underwriting Agreement with Jefferies

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Biomea Fusion...

BMEA : 1.3300 (-2.92%)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Xenon (XENE) and Arcus Biosciences (RCUS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biomea Fusion (BMEA – Research Report), Xenon (XENE – Research Report) and Arcus Biosciences (RCUS –...

BMEA : 1.3300 (-2.92%)
RCUS : 19.46 (+0.78%)
XENE : 38.41 (+0.42%)
Biomea Fusion Announces Positive Phase II Study Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

BMEA : 1.3300 (-2.92%)
Biomea Fusion Announces Pricing of Public Offering of Securities

SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced...

BMEA : 1.3300 (-2.92%)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.4733
2nd Resistance Point 1.4367
1st Resistance Point 1.4033
Last Price 1.3300
1st Support Level 1.3333
2nd Support Level 1.2967
3rd Support Level 1.2633

See More

52-Week High 8.1800
Fibonacci 61.8% 5.5213
Fibonacci 50% 4.7000
Fibonacci 38.2% 3.8787
Last Price 1.3300
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar